Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1628 1629 1691
This examiner grants 48% of resolved cases
Andrew P. Lee serves in Tech Center 1600 and Art Unit 1621. The examiner has 594 resolved cases, with an allowance rate of 48.3 percent. This rate suggests a balanced examination style where roughly half of the resolved cases result in a patent grant. The 48.3 percent allowance rate is a key baseline for applicants in this art unit.
The interview lift is 23.1 percent. This metric highlights the effectiveness of interviews in this examiner's practice. By conducting an interview, practitioners can significantly improve the chances of moving a case toward allowance, nearly doubling the likelihood of success in some scenarios. The 23.1 percent lift is a critical strategic tool for those working in Art Unit 1621.
The median days to allowance is 1214. This timeline is a key consideration for applicants in the biological or chemical arts handled by Tech Center 1600. The data from 594 cases provides a robust foundation for understanding the examiner's historical performance. The 1214-day median pendency helps in managing client expectations for the duration of prosecution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17771737 | THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18279232 | Small Molecule Degraders of CBP/p300 Proteins | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18466041 | IMPROVED ANIMAL FEED COMPOSITIONS AND METHODS OF USE | Final Rejection | Syngenta Participations AG |
| 16972873 | Modified Nucleobases with Uniform H-Bonding Interactions, Homo- and Hetero-Basepair Bias, and Mismatch Discrimination | Final Rejection | Carnegie Mellon University |
| 18731608 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Non-Final OA | Gilead Sciences, Inc. |
| 18673168 | ANTIVIRAL COMPOUNDS | Final Rejection | Gilead Sciences, Inc. |
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | Non-Final OA | Gilead Sciences, Inc. |
| 18336712 | THE MODE OF ACTION OF N-MeDCPA ON TRPC CHANNELS | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 17781778 | DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH | Non-Final OA | Toray Industries, Inc. |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18119724 | TOPICAL COMPOSITIONS AND METHODS OF FORMULATING SAME | Non-Final OA | CMPD Licensing, LLC |
| 17728078 | TOPICAL COMPOSITIONS AND METHODS OF FORMULATING THE SAME | Final Rejection | CMPD Licensing, LLC |
| 16979084 | COMPOSITIONS AND METHODS FOR MUTATIONS ASSOCIATED WITH SUDDEN UNEXPECTED DEATH IN PEDIATRICS | Non-Final OA | Children's Medical Center Corporation |
| 18655854 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | Non-Final OA | Thomas Jefferson University |
| 17127867 | METHODS OF SCHIZOPHRENIA TREATMENT | Final Rejection | INTRA-CELLULAR THERAPIES, INC. |
| 18677401 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | Non-Final OA | AUSPEX PHARMACEUTICALS, INC. |
| 18916596 | Novel Beta-Alanine Compositions and Methods of Use Thereof | Final Rejection | Natural Alternatives International, Inc. |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | Dompe' farmaceutici SpA |
| 16604151 | P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF | Final Rejection | City of Hope |
| 18009312 | Compositions Comprising Antimicrobials and (Bio)-Alkanediols for Skin Protection | Final Rejection | Symrise AG |
| 17920260 | ELAFIBRANOR FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS | Non-Final OA | Genfit |
| 18019959 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION | Final Rejection | SEN-JAM PHARMACEUTICAL LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy